文献速递前列腺癌

新诊断转移性前列腺癌的激素治疗:基于加州癌症登记的人群研究

Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-10-05

基于加州癌症登记数据,纳入2010至2018年新诊断转移性前列腺癌(IV期)且年龄≥20岁的男性,评估初始接受雄激素剥夺治疗(ADT)的比例。共识别13680例患者,21.8%未接受ADT;多因素回归显示高Gleason评分(8-10)和远处转移与更可能接受ADT相关,最低社会经济地位社区与更不可能接受ADT相关,种族/民族间无差异。

要点

  • 新诊断转移性前列腺癌患者中21.8%未接受ADT。
  • Gleason评分8-10者接受ADT的OR为2.04(95%CI 1.82-2.27,P<0.001)。
  • 远处转移者接受ADT的OR为4.02(95%CI 3.62-4.46,P<0.001)。

核心结论

  • 尽管近年来转移性前列腺癌治疗取得显著进展,超过五分之一患者未接受ADT,而ADT是所有新型全身治疗的基础。
  • 该数据集可能有助于解决加州部分前列腺癌诊疗差异。

研究设计与样本

  • 利用加州癌症登记数据的人群研究,纳入2010至2018年新诊断转移性前列腺癌(IV期)且年龄≥20岁的男性。
  • 共识别13680例患者,其中3637例仅有局部转移(N1),9596例有远处转移(M1)伴或不伴N1病变。
  • 采用卡方检验和校正协变量的逻辑回归评估接受激素治疗与患者/肿瘤特征的关联。

主要发现

  • 21.8%(n=2980)的男性未接受ADT。
  • 接受ADT比例最高为75-84岁组(81.6%),最低为85岁以上组(76.0%)。
  • 亚洲男性接受ADT比例最大(n=962,81.5%),其余亚组接受ADT比例相似(76.8%至77.2%)。
  • 校正协变量后,Gleason评分较高(8-10)者更可能接受ADT(OR 2.04,95%CI 1.82-2.27,P<0.001)。
  • 有远处转移部位者更可能接受ADT(OR 4.02,95%CI 3.62-4.46,P<0.001);居住于最低社会经济地位社区者最不可能接受ADT(OR 0.79,95%CI 0.68-0.93,P=0.0032);种族/民族间未观察到接受ADT的差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To evaluate how often men with metastatic prostate cancer (mPC) receive standard of care treatment with androgen deprivation therapy (ADT). METHODS: Men aged ≥20 years with newly diagnosed mPC (stage IV) between 2010 and 2018 were identified using California Cancer Registry data. Receipt of hormonal therapy as initial cancer treatment was examined by patient/tumor characteristics at time of diagnosis. Chi-square tests and logistic regression, adjusted for covariates, were performed to assess association between receipt of hormonal therapy and patient/tumor characteristics. RESULTS: We identified 13,680 men with newly diagnosed mPC, of which 3637 had local metastasis (N1) only while 9596 had distant metastasis (M1) with or without N1 disease. 21.8 % (n = 2980) of men did not receive ADT. The highest rate of receiving ADT was among men between ages 75-84 (81.6%) and the lowest rate was in men over 85 (76.0%). Asian men had the largest proportion receiving ADT (n = 962, 81.5%) with remaining subgroups having similar proportion of men receiving ADT (76.8% to 77.2%). Once adjusted for covariates, regression results showed men with a higher Gleason score (8-10) were more likely to receive ADT (OR 2.04, 1.82-2.27, p = < 0.001) as well as men with distant sites of metastatic disease (OR 4.02, 3.62-4.46, p = < 0.001). Men residing in neighborhoods with the lowest socioeconomic status were least likely to receive ADT (OR 0.79, 0.68-0.93, p = 0.0032). No differences in receipt of ADT were observed by race/ethnicity. DISCUSSION: Despite significant advancements in the treatment of mPC in recent years, over one-fifth of patients did not receive ADT, which is the backbone for all new systemic therapies. This dataset might help address some of the prostate cancer care disparities in California.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Benjamin DJ, Shrestha A, Fellman D, et al. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate Cancer Prostatic Dis. 2023. PMID: 37798437. doi:10.1038/s41391-023-00732-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。